NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Forecast, Price & News $11.76 -0.16 (-1.34%) (As of 05/26/2023 08:47 PM ET) Add Compare Share Share Today's Range$11.50▼$12.3950-Day Range$11.59▼$18.0152-Week Range$5.59▼$24.38Volume39,700 shsAverage Volume47,377 shsMarket Capitalization$390.43 millionP/E RatioN/ADividend YieldN/APrice Target$21.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Entrada Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside82.8% Upside$21.50 Price TargetShort InterestBearish6.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.90Based on 7 Articles This WeekInsider TradingSelling Shares$165,835 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.56) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector860th out of 1,012 stocksPharmaceutical Preparations Industry429th out of 495 stocks 3.3 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Entrada Therapeutics has a forecasted upside of 82.8% from its current price of $11.76.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.73% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 26.3, which indicates bearish sentiment.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 2.7 News and Social Media Coverage News SentimentEntrada Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Entrada Therapeutics this week, compared to 1 article on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $165,835.00 in company stock.Percentage Held by InsidersOnly 7.22% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions78.08% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.56) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entrada Therapeutics (NASDAQ:TRDA) StockEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Stock News HeadlinesMay 18, 2023 | marketbeat.comVertex Pharmaceuticals Hits Record High on Strong Q1 Earnings (TRDA)Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.May 26, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Entrada Therapeutics, Inc. Boosted by HC Wainwright (NASDAQ:TRDA)May 29, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 24, 2023 | msn.comHC Wainwright & Co. Reiterates Entrada Therapeutics (TRDA) Buy RecommendationMay 24, 2023 | markets.businessinsider.comEntrada Therapeutics Inc (TRDA) Receives a Buy from H.C. WainwrightMay 16, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Entrada Therapeutics, Inc. (NASDAQ:TRDA) Boosted by AnalystMay 15, 2023 | finance.yahoo.comSome Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EstimatesMay 13, 2023 | finance.yahoo.comEntrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 29, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 13, 2023 | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) to Post FY2027 Earnings of ($4.16) Per Share, William Blair ForecastsMay 11, 2023 | marketwatch.com8-K: Entrada Therapeutics, Inc.May 11, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Hold Rating for Entrada Therapeutics Inc (TRDA)May 10, 2023 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comEntrada Therapeutics Reports First Quarter 2023 Financial ResultsMay 4, 2023 | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Sells $27,420.00 in StockApril 30, 2023 | finance.yahoo.comWe Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth CarefullyApril 25, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Entrada Therapeutics Inc (TRDA)April 21, 2023 | americanbankingnews.comDipal Doshi Sells 2,092 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockApril 21, 2023 | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Insider Sells $71,298.00 in StockApril 7, 2023 | americanbankingnews.comBrokers Issue Forecasts for Entrada Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:TRDA)April 5, 2023 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Coverage Initiated at HC WainwrightApril 4, 2023 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of DirectorsApril 4, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Entrada Therapeutics (TRDA) with Buy RecommendationApril 4, 2023 | finance.yahoo.comEntrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of DirectorsApril 1, 2023 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) and Verrica Pharmaceuticals (NASDAQ:VRCA) Head-To-Head ComparisonMarch 30, 2023 | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CEO Dipal Doshi Sells 2,000 Shares of StockMarch 29, 2023 | finance.yahoo.comEntrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Company Calendar Last Earnings3/06/2023Today5/28/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees114Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+82.8%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,620,000.00 Net MarginsN/A Pretax Margin-301.14% Return on Equity-34.19% Return on Assets-24.54% Debt Debt-to-Equity RatioN/A Current Ratio2.94 Quick Ratio2.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.92 per share Price / Book1.70Miscellaneous Outstanding Shares33,200,000Free Float30,800,000Market Cap$390.43 million OptionableNot Optionable Beta-0.82 Key ExecutivesMr. Dipal Doshi (Age 46)Pres, CEO & Director Comp: $788.11kMr. Nathan J. Dowden (Age 51)Chief Operating Officer Comp: $605.45kDr. Natarajan Sethuraman Ph.D. (Age 60)Chief Scientific Officer Comp: $621.87kMr. Kory James Wentworth CPA (Age 42)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., Gen. CounselMs. Kerry Robert M.S.VP of PeopleDr. Nerissa C. Kreher M.B.A. (Age 49)M.D., M.S., Chief Medical Officer Ms. Karla MacDonaldChief Corp. Affairs OfficerMore ExecutivesKey CompetitorsEmergent BioSolutionsNYSE:EBSArbutus BiopharmaNASDAQ:ABUSAerovate TherapeuticsNASDAQ:AVTEErascaNASDAQ:ERASOrganogenesisNASDAQ:ORGOView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 947 shares on 5/18/2023Ownership: 0.026%Susquehanna International Group LLPBought 84,716 shares on 5/16/2023Ownership: 0.592%Geode Capital Management LLCBought 1,833 shares on 5/16/2023Ownership: 0.554%Jane Street Group LLCBought 59,374 shares on 5/16/2023Ownership: 0.223%Cubist Systematic Strategies LLCBought 3,755 shares on 5/15/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions TRDA Stock - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price forecast for 2023? 3 Wall Street research analysts have issued 12-month price objectives for Entrada Therapeutics' shares. Their TRDA share price forecasts range from $18.00 to $25.00. On average, they anticipate the company's stock price to reach $21.50 in the next year. This suggests a possible upside of 82.8% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2023? Entrada Therapeutics' stock was trading at $13.52 at the beginning of 2023. Since then, TRDA shares have decreased by 13.0% and is now trading at $11.76. View the best growth stocks for 2023 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings results on Monday, March, 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.04. When did Entrada Therapeutics IPO? (TRDA) raised $182 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 9,075,000 shares at $19.00-$21.00 per share. What is Entrada Therapeutics' stock symbol? Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA." Who are Entrada Therapeutics' major shareholders? Entrada Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (8.99%), Wellington Management Group LLP (3.06%), FMR LLC (1.60%), BlackRock Inc. (0.64%), Susquehanna International Group LLP (0.59%) and Geode Capital Management LLC (0.55%). Insiders that own company stock include Bros Advisors Lp Baker, Dipal Doshi, John F Crowley, Kory James Wentworth, Natarajan Sethuraman, Nathan J Dowden and Nerissa Kreher. View institutional ownership trends. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entrada Therapeutics' stock price today? One share of TRDA stock can currently be purchased for approximately $11.76. How much money does Entrada Therapeutics make? Entrada Therapeutics (NASDAQ:TRDA) has a market capitalization of $390.43 million. The company earns $-94,620,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. How many employees does Entrada Therapeutics have? The company employs 114 workers across the globe. How can I contact Entrada Therapeutics? The official website for the company is www.entradatx.com. The company can be reached via phone at 857-520-9158 or via email at investors@entradatx.com. This page (NASDAQ:TRDA) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.